Fintech

Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

Published

2 years ago

November 21, 2022

Newsfile

New York, New York–(Newsfile Corp. – November 21, 2022) – PCG Digital — Lexaria Bioscience (NASDAQ: LEXX) is investigating the potential therapeutic utility of its proprietary DehydraTECH^TM-CBD against dementia and diabetes, two of the world’s biggest public health crises.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/145019

Related Topics:fintech

Fintech7 days ago

Fintech Pulse: Your Daily Industry Brief (Nuvei, Google, Upvest, Gen Digital, MoneyLion)
Fintech3 days ago

Fintech Pulse: Your Daily Industry Brief (Synapse, Shenzhen Institute, Visa, AutomatIQ, MeridianLink)
Fintech PR6 days ago

A New Era of $WUSD — Revolutionizing Stablecoins with Unmatched Security, Stability and Next-Gen Innovation
Fintech PR7 days ago

Cathay Financial Holdings Calls for Climate Finance Mobilization to Drive the Climate Industrial Revolution
Fintech PR6 days ago

Lanistar launches new gaming sites in Brazil as secures right to operate pending final approval on its licence
Fintech2 days ago

Fintech Pulse: Your Daily Industry Brief (Revolut, Bestow, Advyzon, Tyme Group, Nubank)

The Fintech Buzz

Fintech

Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

Trending